DossierENTITY

Blockbuster drugs

Coverage of Blockbuster drugs in the Nexus archive.

Earliest in view: Jul 21 · 23:16 UTCMost recent: Jul 21 · 23:16 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJul 21 · 23:16 UTCSEMAFOR
Fervor over top-selling drugs fuels biotech dealmaking
Biotech firms are attracting significant dealmaking and investor interest, with 37 biotech acquisitions over $1 billion this year driven by pharma companies seeking to strengthen pipelines before patent expirations. The Trump administration’s regulatory approach and profits from top-selling drugs are fueling mergers, while biotech IPOs are outperforming AI-related listings.